Dec. 4 (Bloomberg) -- Eisai Co. bought the rights to an experimental Alzheimer's disease treatment from BioArctic Neuroscience AB, giving the Japanese drugmaker another potential successor to its best-seller, Aricept. Eisai, Japan's fourth-largest drugmaker, has the global rights to study, develop, manufacture and market the drug, known as BAN2401, under an agreement signed yesterday with Stockholm- based BioArctic Neuroscience. No financial terms were disclosed.
